In December 2025, the FDA approved Novo Nordisk’s oral Wegovy, marking the first oral GLP-1 therapy for chronic weight management, with prices starting at $149 per month. This move has intensified competition and policy changes in obesity treatment, as commercial payers seek rebates and competitors align their pricing to match MFN benchmarks. Direct-to-patient (DTP) programs, such as LillyDirect and NovoCare, are improving adherence by offering predictable pricing, home delivery, and additional support, resulting in adherence rates comparable to those with commercial insurance. Companies are now enhancing these DTP strategies with innovations like refill automation and digital coaching, aiming to improve patient care and long-term health outcomes.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.iqvia.com/locations/united-states/blogs/2026/02/non-traditional-channels-the-growth-of-direct-to-patient-programs
